Blog
RSS FeedPosted by Michael Wonder on 17 May 2026
MHRA approves beremagene geperpavec (Vyjuvek) for the treatment of dystrophic epidermolysis bullosa
15 May 2026 - The MHRA has today approved beremagene geperpavec (Vyjuvek) for the treatment of wounds in patients with dystrophic ...
Posted by Michael Wonder on 15 May 2026
Routine NHS access to spinal muscular atrophy treatments offers new hope for patients and families
14 May 2026 - People living with spinal muscular atrophy in England are set to gain routine access to two potentially ...
Posted by Michael Wonder on 15 May 2026
Over 1,500 people set to benefit from first immunotherapy for aggressive stomach cancer
14 May 2026 - Over 1,500 people set to benefit from first immunotherapy for aggressive stomach cancer. ...
Posted by Michael Wonder on 08 May 2026
NICE approves Duchenne muscular dystrophy treatment givinostat after commercial deal sealed
8 May 2026 - Around 530 people in England will benefit from access to the Duchenne muscular dystrophy treatment givinostat, following ...
Posted by Michael Wonder on 08 May 2026
MHRA approves donidalorsen (Dawnzera) for the treatment of hereditary angioedema
7 May 2026 - The MHRA has today approved donidalorsen (Dawnzera) for use in patients 12 years and older with hereditary angioedema to ...
Posted by Michael Wonder on 02 May 2026
MHRA approves Linerixibat (Lynavoy) for the treatment of itch due to biliary tract disease
1 May 2026 - The MHRA has today approved Linerixibat (Lynavoy) for use to treat an itch in adults with primary biliary cholangitis. ...
Posted by Michael Wonder on 30 Apr 2026
First NICE recommended treatment for uncontrolled generalised myasthenia gravis
29 April 2026 - We’ve recommended a new treatment called rozanolixizumab for some adults living with generalised myasthenia gravis whose ...
Posted by Michael Wonder on 23 Apr 2026
Enflonsia (clesrovimab-cfor) approved to prevent RSV in newborns and infants
22 April 2026 - The MHRA has today approved the medicine Enflonsia (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) ...
Posted by Michael Wonder on 22 Apr 2026
New life-extending treatment given the green light for people with rare form of bile duct cancer
21 April 2026 - A new targeted treatment for a rare and aggressive form of bile duct cancer has been recommended ...
Posted by Michael Wonder on 19 Apr 2026
New take at home drug recommended for people with chronic lymphocytic leukaemia
17 April 2026 - NICE has recommended a new take at home tablet for some people with chronic lymphocytic leukaemia whose ...
Posted by Michael Wonder on 16 Apr 2026
‘Trojan horse’ treatment recommended for people with multiple myeloma
16 April 2026 - Around 1,600 people a year in England with multiple myeloma are set to benefit from a ...
Posted by Michael Wonder on 11 Apr 2026
MHRA approves olezarsen (Tryngolza) for the treatment of familial chylomicronaemia syndrome
10 April 2026 - The MHRA has today approved olezarsen (Tryngolza) to help treat adults with familial chylomicronaemia syndrome. ...
Posted by Michael Wonder on 08 Apr 2026
Access Consortium sets 2026 priorities to accelerate work-sharing and improve patient access to innovative medicines
7 April 2026 - The MHRA-led Access Consortium 2026 action plan will deepen collaboration, streamline work sharing, and speed up access ...
Posted by Michael Wonder on 03 Apr 2026
Sevabertinib approved to treat adults with HER2 positive lung cancer that has spread or cannot be removed by surgery
2 April 2026 - The MHRA has approved sevabertinib (Hyrnuo) to treat adults with advanced non-small cell lung cancer with ...
Posted by Michael Wonder on 03 Apr 2026
NHS patients and British businesses to benefit from historic changes to medicines access following pharmaceutical partnership with US
2 April 2026 - New partnership accelerates NHS patients' access to new medicines and will see UK benefit from greater life ...